{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:32:19Z","timestamp":1777519939574,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of Review<\/jats:title>\n            <jats:p>This review discusses whether patients\u2019 genotype affects the efficacy of PCSK9 inhibitors in treating familial hypercholesterolemia and how this might influence clinical management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>Currently, available evidence consistently demonstrates and is in good agreement that, in general, the LDL-C-lowering effect of PCSK9 inhibitors is similar across genotypes, except for compound heterozygous and homozygous familial hypercholesterolemia (FH). However, it remains to be seen whether the comparable therapeutic effect in lowering LDL-C level also leads to a comparable degree of cardiovascular risk reduction with different genotypes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Generally, the level of LDL-C reduction following PCSK9 inhibitor treatment is similar within different genotypes. Hence, genotype is a less reliable predictor for further LDL-C level reduction on PCSK9 inhibitor therapy, and attention should be given to other external influences, especially for heterozygous FH.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10557-023-07505-5","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T06:02:32Z","timestamp":1692770552000},"page":"405-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-1463","authenticated-orcid":false,"given":"Fistra Janrio","family":"Tandirerung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"issue":"9","key":"7505_CR1","doi-asserted-by":"publisher","first-page":"e018932","DOI":"10.1161\/JAHA.120.018932","volume":"10","author":"L D\u2019erasmo","year":"2021","unstructured":"D\u2019erasmo L, Minicocci I, Di Costanzo A, Pigna G, Commodari D, Ceci F, et al. Clinical implications of monogenic versus polygenic hypercholesterolemia: long-term response to treatment, coronary atherosclerosis burden, and cardiovascular events. J Am Heart Assoc. 2021;10(9):e018932.","journal-title":"J Am Heart Assoc"},{"key":"7505_CR2","doi-asserted-by":"publisher","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","volume":"3","author":"JC Defesche","year":"2017","unstructured":"Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Prim. 2017;3:17093.","journal-title":"Nat Rev Dis Prim"},{"issue":"October","key":"7505_CR3","first-page":"1","volume":"11","author":"M Vrablik","year":"2020","unstructured":"Vrablik M, Tich\u00fd L, Freiberger T, Blaha V, Satny M, Hubacek JA. Genetics of familial hypercholesterolemia: new insights. Front Genet. 2020;11(October):1\u201310.","journal-title":"Front Genet"},{"issue":"2","key":"7505_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-014-0482-5","volume":"17","author":"S Singh","year":"2015","unstructured":"Singh S, Bittner V. Familial hypercholesterolemia\u2014epidemiology, diagnosis, and screening. Curr Atheroscler Rep. 2015;17(2):1\u20138.","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"7505_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-019-1130-z","volume":"21","author":"M Sharifi","year":"2019","unstructured":"Sharifi M, Futema M, Nair D, Humphries SE. Polygenic hypercholesterolemia and cardiovascular disease risk. Curr Cardiol Rep. 2019;21(6):1\u20136.","journal-title":"Curr Cardiol Rep"},{"issue":"45","key":"7505_CR6","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013;34(45):3478\u201390.","journal-title":"Eur Heart J"},{"issue":"2","key":"7505_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/MOL.0000000000000741","volume":"32","author":"AJ Cupido","year":"2021","unstructured":"Cupido AJ, Tromp TR, Hovingh GK. The clinical applicability of polygenic risk scores for LDL-cholesterol: considerations, current evidence and future perspectives. Curr Opin Lipidol. 2021;32(2):112\u20136.","journal-title":"Curr Opin Lipidol"},{"issue":"11","key":"7505_CR8","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s11886-022-01783-5","volume":"24","author":"FJ Tandirerung","year":"2022","unstructured":"Tandirerung FJ. The clinical importance of differentiating monogenic familial hypercholesterolemia from polygenic hypercholesterolemia. Curr Cardiol Rep. 2022;24(11):1669\u201377.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"7505_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1743-7075-8-23","volume":"8","author":"AC Fahed","year":"2011","unstructured":"Fahed AC, Nemer GM. Familial hypercholesterolemia: the lipids or the genes? Nutr Metab. 2011;8(1):23.  Available from: http:\/\/www.nutritionandmetabolism.com\/content\/8\/1\/23","journal-title":"Nutr Metab"},{"issue":"1","key":"7505_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2013.12.028","volume":"233","author":"PCJL Santos","year":"2014","unstructured":"Santos PCJL, Morgan AC, Jannes CE, Turolla L, Krieger JE, Santos RD, et al. Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2014;233(1):206\u201310.","journal-title":"Atherosclerosis"},{"issue":"4","key":"7505_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/01213011-200504000-00005","volume":"15","author":"G Miltiadous","year":"2005","unstructured":"Miltiadous G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf MS. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet Genomics. 2005;15(4):219\u201325.","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"7505_CR12","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1210\/jcem.86.10.7899","volume":"86","author":"FJ Chaves","year":"2001","unstructured":"Chaves FJ, Real JT, Garc\u00eda-Gaci\u00e1A AB, Civera M, Armengod ME, Ascaso JF, et al. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. J Clin Endocrinol Metab. 2001;86(10):4926\u201332.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"7505_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cjco.2019.02.005","volume":"1","author":"T Lee","year":"2019","unstructured":"Lee T, Iacocca MA, Ban MR, Hegele RA. Efficacy of evolocumab in monogenic vs polygenic hypercholesterolemia. CJC Open. 2019;1(3):115\u20138.","journal-title":"CJC Open"},{"issue":"1","key":"7505_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-016-0256-1","volume":"23","author":"R Henderson","year":"2016","unstructured":"Henderson R, O\u2019Kane M, McGilligan V, Watterson S. The genetics and screening of familial hypercholesterolaemia. J Biomed Sci. 2016;23(1):1\u201312.","journal-title":"J Biomed Sci"},{"issue":"1","key":"7505_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-017-0488-4","volume":"16","author":"CS Paththinige","year":"2017","unstructured":"Paththinige CS, Sirisena ND, Dissanayake VHW. Genetic determinants of inherited susceptibility to hypercholesterolemia - a comprehensive literature review. Lipids Health Dis. 2017;16(1):1\u201322.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"7505_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1399-0004.1994.tb03999.x","volume":"45","author":"G Schl\u00fcter","year":"1994","unstructured":"Schl\u00fcter G, Wick U. An 87 bp deletion in exon 5 of the LDL receptor gene in a mother and her son with familial hypercholesterolemia. Clin Genet. 1994;45(2):84\u20137.","journal-title":"Clin Genet"},{"issue":"2","key":"7505_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.arcmed.2019.12.017","volume":"51","author":"TDJ Hern\u00e1ndez Flores","year":"2020","unstructured":"Hern\u00e1ndez Flores TDJ, Gonz\u00e1lez Garc\u00eda JR, S\u00e1nchez L\u00f3pez YJ, V\u00e1zquez C\u00e1rdenas NA, Colima Fausto AG, Rodr\u00edguez Preciado SY, et al. LDLR Gene mutation p.Asp360His and familial hypercholesterolemia in a Mexican community. Arch Med Res. 2020;51(2):153\u20139.","journal-title":"Arch Med Res."},{"issue":"3","key":"7505_CR18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients. J Clin Lipidol. 2011;5(3):S1-8.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"7505_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jjcc.2017.07.002","volume":"71","author":"M Ogura","year":"2018","unstructured":"Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2018;71(1):1\u20137.","journal-title":"J Cardiol"},{"issue":"11","key":"7505_CR20","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.3390\/ijms19113426","volume":"19","author":"A Benito-Vicente","year":"2018","unstructured":"Benito-Vicente A, Uribe KB, Jebari S, Galicia-Garcia U, Ostolaza H, Martin C. Familial hypercholesterolemia: the most frequent cholesterol metabolism disorder caused disease. Int J Mol Sci. 2018;19(11):3426.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"7505_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/ncpcardio0836","volume":"4","author":"AK Soutar","year":"2007","unstructured":"Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214\u201325.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"2","key":"7505_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154\u20136.","journal-title":"Nat Genet"},{"issue":"1","key":"7505_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2009.11.018","volume":"210","author":"T Noguchi","year":"2010","unstructured":"Noguchi T, Katsuda S, Kawashiri MA, Tada H, Nohara A, Inazu A, et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis. 2010;210(1):166\u201372.","journal-title":"Atherosclerosis"},{"issue":"12","key":"7505_CR24","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1161\/01.ATV.0000190668.94752.ab","volume":"25","author":"RP Naoumova","year":"2005","unstructured":"Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, Marais AD, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol. 2005;25(12):2654\u201360.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"7505_CR25","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/14740338.2019.1681395","volume":"18","author":"Z Iqbal","year":"2019","unstructured":"Iqbal Z, Dhage S, Mohamad JB, Abdel-Razik A, Donn R, Malik R, et al. Efficacy and safety of PCSK9 monoclonal antibodies. Expert Opin Drug Saf. 2019;18(12):1191\u2013201.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"7505_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14656566.2019.1702970","volume":"21","author":"A Pasta","year":"2020","unstructured":"Pasta A, Cremonini AL, Pisciotta L, Buscaglia A, Porto I, Barra F, et al. PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin Pharmacother. 2020;21(3):353\u201363.","journal-title":"Expert Opin Pharmacother"},{"issue":"22","key":"7505_CR27","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"18","key":"7505_CR28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"7505_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","volume":"76","author":"DJ Blom","year":"2020","unstructured":"Blom DJ, Harada-Shiba M, Rubba P, Gaudet D, Kastelein JJP, Charng MJ, et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial. J Am Coll Cardiol. 2020;76(2):131\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"9965","key":"7505_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, et al. PCSK9 inhibition with evolocumab ( AMG 145) in heterozygous familial hypercholesterolaemia ( RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331\u201340.","journal-title":"Lancet"},{"issue":"6","key":"7505_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40256-021-00477-7","volume":"21","author":"J Hardy","year":"2021","unstructured":"Hardy J, Niman S, Pereira E, Lewis T, Reid J, Choksi R, et al. A critical review of the efficacy and safety of inclisiran. Am J Cardiovasc Drugs. 2021;21(6):629\u201342.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"16","key":"7505_CR32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"key":"7505_CR33","first-page":"1520","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Phil M, Turner T, Koenig W, Wright RS, Wijngaard PLJ, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. 2020;382:1520\u201330.","journal-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia."},{"issue":"5","key":"7505_CR34","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1038\/mtna.2012.16","volume":"1","author":"T Yamamoto","year":"2012","unstructured":"Yamamoto T, Harada-Shiba M, Nakatani M, Wada S, Yasuhara H, Narukawa K, et al. Cholesterol-lowering action of BNA-based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice. Mol Ther - Nucleic Acids. 2012;1(5):e22.","journal-title":"Mol Ther - Nucleic Acids"},{"issue":"6","key":"7505_CR35","first-page":"100513","volume":"1","author":"RW King","year":"2022","unstructured":"King RW, Canonico ME, Bonaca MP, Hess CN. Management of peripheral arterial disease: lifestyle modifications and medical therapies. J Soc Cardiovasc Angiogr Interv. 2022;1(6):100513.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"9","key":"7505_CR36","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","volume":"74","author":"JW Jukema","year":"2019","unstructured":"Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;74(9):1167\u201376.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"7505_CR37","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137(4):338\u201350.","journal-title":"Circulation"},{"issue":"2","key":"7505_CR38","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1097\/FJC.0000000000001053","volume":"78","author":"BA Warden","year":"2021","unstructured":"Warden BA, Barton Duell P. Inclisiran: A novel agent for lowering apolipoprotein B\u2013containing lipoproteins. J Cardiovasc Pharmacol. 2021;78(2):e157\u201374. Available from: https:\/\/journals.lww.com\/cardiovascularpharm\/Abstract\/2021\/08000\/Inclisiran__A_Novel_Agent_for_Lowering.1.aspx","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"7505_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/14712598.2020.1677604","volume":"20","author":"D Steffens","year":"2020","unstructured":"Steffens D, Bramlage P, Scheeff C, Kasner M, Hassanein A, Friebel J, et al. PCSK9 inhibitors and cardiovascular outcomes. Expert Opin Biol Ther. 2020;20(1):35\u201347.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"7505_CR40","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2217\/fca-2020-0150","volume":"17","author":"J Brandts","year":"2021","unstructured":"Brandts J, Ray KK. Clinical implications and outcomes of the ORION phase III trials. Future Cardiol. 2021;17(5):769\u201377.","journal-title":"Future Cardiol"},{"issue":"16","key":"7505_CR41","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"C Ballantyne","year":"2023","unstructured":"Ballantyne C, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"7505_CR42","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.numecd.2021.10.025","volume":"32","author":"G Iannuzzo","year":"2022","unstructured":"Iannuzzo G, Buonaiuto A, Calcaterra I, Gentile M, Forte F, Tripaldella M, et al. Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: a single center real-world study. Nutr Metab Cardiovasc Dis. 2022;32(3):684\u201391.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"7505_CR43","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.jacl.2017.08.016","volume":"11","author":"JC Defesche","year":"2017","unstructured":"Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-dinet MT, et al. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017;11(6):1338-1346.e7.","journal-title":"J Clin Lipidol"},{"issue":"16","key":"7505_CR44","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330.","journal-title":"N Engl J Med"},{"issue":"6","key":"7505_CR45","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758\u201369.","journal-title":"J Clin Lipidol"},{"issue":"32","key":"7505_CR46","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146\u201357.","journal-title":"Eur Heart J"},{"issue":"12","key":"7505_CR47","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1172\/JCI200318925","volume":"111","author":"DJ Rader","year":"2003","unstructured":"Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111(12):1795\u2013803.","journal-title":"J Clin Invest"},{"issue":"3","key":"7505_CR48","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","volume":"38","author":"A Thedrez","year":"2018","unstructured":"Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, et al. Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of evolocumab. Arterioscler Thromb Vasc Biol. 2018;38(3):592\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9874","key":"7505_CR49","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(13)60187-7","volume":"381","author":"EA Stein","year":"2013","unstructured":"Stein EA, Raal FJ. Polygenic familial hypercholesterolaemia: does it matter? Lancet. 2013;381(9874):1255\u20137.","journal-title":"Lancet"},{"key":"7505_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/10742484221100107","volume":"27","author":"C Coppinger","year":"2022","unstructured":"Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M. A comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther. 2022;27:1\u201314.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"7","key":"7505_CR51","doi-asserted-by":"publisher","first-page":"665","DOI":"10.5551\/jat.RV17050","volume":"28","author":"A Nohara","year":"2021","unstructured":"Nohara A, Tada H, Ogura M, Okazaki S, Ono K, Shimano H, et al. Homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2021;28(7):665\u201378.","journal-title":"J Atheroscler Thromb"},{"issue":"20","key":"7505_CR52","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","volume":"124","author":"FJ Raal","year":"2011","unstructured":"Raal FJ, Pilcher GJ, Panz VR, Van Deventer HE, Brice BC, Blom DJ, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124(20):2202\u20137.","journal-title":"Circulation"},{"key":"7505_CR53","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5551\/jat.CR003","volume":"25","author":"M Harada-shiba","year":"2018","unstructured":"Harada-shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25:751\u201370.","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"7505_CR54","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacl.2017.12.008","volume":"12","author":"ML Hartgers","year":"2018","unstructured":"Hartgers ML, Defesche JC, Langslet G, Hopkins PN, Kastelein JJP, Baccara-Dinet MT, et al. Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. J Clin Lipidol. 2018;12(2):390-396.e8.","journal-title":"J Clin Lipidol"},{"issue":"8","key":"7505_CR55","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp L, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"7505_CR56","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/MOL.0000000000000853","volume":"33","author":"TR Tromp","year":"2022","unstructured":"Tromp TR, Cuchel M. New algorithms for treating homozygous familial hypercholesterolemia. Curr Opin Lipidol. 2022;33(6):326\u201335.","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"7505_CR57","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jacc.2020.05.033","volume":"76","author":"GR Thompson","year":"2020","unstructured":"Thompson GR. PCSK9 Inhibitors for homozygous familial hypercholesterolemia: useful but seldom sufficient. J Am Coll Cardiol. 2020;76(2):143\u20135.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"7505_CR58","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA - J Am Med Assoc. 2016;316(12):1289\u201397.","journal-title":"JAMA - J Am Med Assoc"},{"key":"7505_CR59","first-page":"1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:1082\u2013143.","journal-title":"Circulation"},{"key":"7505_CR60","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Kokinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07505-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07505-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07505-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T08:37:23Z","timestamp":1743669443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07505-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7505"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07505-5","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"13 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies involving human or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"No informed consent is required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The author gives the consent for publication of identifiable details.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The author declares no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}